Does dapagliflozin affect the no-reflow phenomenon in patients with type 2 diabetes mellitus and acute myocardial infarction undergoing percutaneous coronary intervention?
This letter to the editor discusses a study on the effect of dapagliflozin on the no-reflow phenomenon in patients with T2DM and acute myocardial infarction undergoing PCI.
To the Editor,We have read the article by Quisi et al. 1 which explored the effect of dapagliflozin on the noreflow phenomenon in patients with type 2 diabetes mellitus (T2DM) and acute myocardia...
Köseoğlu et al. (2025) studied this question.